These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16418399)

  • 41. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of antigen-presenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells.
    Shankar AH; Titus RG
    J Infect Dis; 1997 Jan; 175(1):151-7. PubMed ID: 8985210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine.
    Schwarz T; Remer KA; Nahrendorf W; Masic A; Siewe L; Müller W; Roers A; Moll H
    PLoS Pathog; 2013; 9(6):e1003476. PubMed ID: 23825956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leishmania major inhibits IL-12 in macrophages by signalling through CR3 (CD11b/CD18) and down-regulation of ETS-mediated transcription.
    Ricardo-Carter C; Favila M; Polando RE; Cotton RN; Bogard Horner K; Condon D; Ballhorn W; Whitcomb JP; Yadav M; Geister RL; Schorey JS; McDowell MA
    Parasite Immunol; 2013 Dec; 35(12):409-20. PubMed ID: 23834512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. c-Rel promotes type 1 and type 17 immune responses during Leishmania major infection.
    Reinhard K; Huber M; Wostl C; Hellhund A; Toboldt A; Abass E; Casper B; Joeris T; Herr C; Bals R; Steinhoff U; Lohoff M; Visekruna A
    Eur J Immunol; 2011 May; 41(5):1388-98. PubMed ID: 21469108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
    Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
    J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
    Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
    Front Immunol; 2018; 9():79. PubMed ID: 29459858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages.
    Conrad SM; Strauss-Ayali D; Field AE; Mack M; Mosser DM
    Infect Immun; 2007 Feb; 75(2):653-65. PubMed ID: 17088347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
    Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
    J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process.
    Marovich MA; McDowell MA; Thomas EK; Nutman TB
    J Immunol; 2000 Jun; 164(11):5858-65. PubMed ID: 10820265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
    Remer KA; Apetrei C; Schwarz T; Linden C; Moll H
    Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.
    Radwanska M; Cutler AJ; Hoving JC; Magez S; Holscher C; Bohms A; Arendse B; Kirsch R; Hunig T; Alexander J; Kaye P; Brombacher F
    PLoS Pathog; 2007 May; 3(5):e68. PubMed ID: 17500591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice.
    Carter CR; Whitcomb JP; Campbell JA; Mukbel RM; McDowell MA
    Infect Immun; 2009 Dec; 77(12):5668-75. PubMed ID: 19797068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation.
    Sato N; Ahuja SK; Quinones M; Kostecki V; Reddick RL; Melby PC; Kuziel WA; Ahuja SS
    J Exp Med; 2000 Jul; 192(2):205-18. PubMed ID: 10899907
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against Leishmania major.
    Schnitzer JK; Berzel S; Fajardo-Moser M; Remer KA; Moll H
    Vaccine; 2010 Aug; 28(36):5785-93. PubMed ID: 20615489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leishmania-infected MHC class IIhigh dendritic cells polarize CD4+ T cells toward a nonprotective T-bet+ IFN-γ+ IL-10+ phenotype.
    Resende M; Moreira D; Augusto J; Cunha J; Neves B; Cruz MT; Estaquier J; Cordeiro-da-Silva A; Silvestre R
    J Immunol; 2013 Jul; 191(1):262-73. PubMed ID: 23729437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis.
    Liese J; Schleicher U; Bogdan C
    Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.
    Belkaid Y; Von Stebut E; Mendez S; Lira R; Caler E; Bertholet S; Udey MC; Sacks D
    J Immunol; 2002 Apr; 168(8):3992-4000. PubMed ID: 11937556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigations on the effects of anti-Leishmania major serum on the progression of Leishmania infantum infection in vivo and in vitro - implications of heterologous exposure to Leishmania spp.
    McNolty A; Anderson H; Stryker GA; Dondji B
    Parasitol Res; 2021 May; 120(5):1771-1780. PubMed ID: 33792813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two waves of antigen-containing dendritic cells in vivo in experimental Leishmania major infection.
    Misslitz AC; Bonhagen K; Harbecke D; Lippuner C; Kamradt T; Aebischer T
    Eur J Immunol; 2004 Mar; 34(3):715-725. PubMed ID: 14991601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.